Tecan and Covaris Co-Market Freedom EVO® with Adaptive Focused Acoustics™

Covaris Tecan press release pictureMännedorf, Switzerland—November 18, 2010—Tecan is collaborating with Covaris, Inc., a rapidly growing company providing advanced sample preparation solutions for life and analytical science, to co­promote the Freedom EVO® liquid handling platform with integrated Adaptive Focused Acoustics™ (AFA). This co-marketing agreement will allow customers to benefit from both the advanced capabilities of Tecan’s Freedom EVO systems and Covaris’ controlled non-contact acoustic sample preparation technology.

Covaris’ AFA systems have already been successfully integrated into the Freedom EVO platform for several applications, and this joint offering will now be available to customers worldwide for sample preparation, compound management and next generation sequencing applications.

Kevin Moore, Tecan’s Director of Market and Application Management for BioPharma, said: “AFA is gaining widespread acceptance in the compound management community for rapid thawing, mixing and dissolution of samples, as well as for DNA shearing in the exciting area of next generation sequencing. We are extremely pleased to be working together with Covaris to provide valuable automated solutions to our customers working in these areas.”

“Covaris is delighted to enter into partnership with Tecan to provide researchers with next generation automated sample preparation,” said Jim Laugharn, Covaris President and CEO. “High quality, reproducible sample preparation is the critical first step in improving analytical results, and Covaris’ highly controlled system sets the standard for today’s rapidly advancing analytical technologies and sophisticated assays. This collaboration between Tecan and Covaris provides scalable, turn-key automated sample preparation solutions for a wide variety of key life science applications.”

To find out more on Tecan’s Freedom EVO workstations, visit http://www.tecan.com/freedomevo
To find out more about our solution, visit http://www.tecan.com/covaris
To find out more on Covaris’ Adaptive Focused Acoustics, visit https://www.covaris.com

For more information please contact
Tecan Trading AG
Tanja Kaiser
Seestrasse 103
CH-8708 Männedorf
Tel +41 (0)44 922 81 11
Fax +41 (0)44 922 81 12
info@tecan.com
www.tecan.com

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

For more information about Covaris Inc., please contact
Covaris, Inc.
Brian Paras
14 Gill Street, Unit H
Woburn, MA  01801
bparas@covaris.com
www.covaris.com
001 781.932.3959 ext. 206

About Covaris, Inc.
Covaris, Inc. (www.covaris.com) provides advanced sample preparation systems for life and analytical sciences. We design, manufacture, and distribute products that support a wide variety of applications including next-generation DNA sequencing, ChIP, proteomics, and compound management. Our patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to sample preparation. The AFA process, which is based on shock wave physics, delivers controlled, precise and accurate acoustic energy to biological and chemical samples. Covaris sells instruments in more than 30 countries throughout the world.

Covaris Signs Co-Marketing Agreement with Illumina to Combine Next-Gen Sequencing Platforms with Controlled DNA Shearing

WOBURN, MA—September 10, 2010—Covaris Inc. (a privately-held MA based company) today announced that it has signed a co-marketing agreement with Illumina, Inc. (NASDAQ:ILMN) making Covaris DNA shearing technologies the recommended method of shearing with Illumina next-generation sequencing product lines, including HiSeq, HiScanSQ, and Genome Analyzer. In addition, the proprietary Covaris process enables higher recoveries for nucleic acid extraction, tissue homogenization, chromatin shearing, protein digestion, and cell lysis. The highly controlled Covaris technology is isothermal and non-contact, ensuring molecular stability throughout the sample preparation process. Important for next-generation genetic analysis, the Covaris system allows customers to rapidly and precisely scale up sample processing capability. The Illumina-Covaris partnership will bring industry leading next-generation DNA shearing performance to Illumina’s sequencing customers

About Covaris, Inc.
Covaris, Inc. provides advanced sample preparation systems for life and analytical science. Our sample prep technologies support a wide variety of applications including next-generation DNA sequencing, ChIP, proteomics, and compound management. Our patented Adaptive Focused Acoustic (AFA) technology enables a high energy density to bring unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples.

Information about Covaris is available at https://www.covaris.com.

Contact:
Brian J. Paras
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
bparas@covaris.com
Tel: 001 781.932.3959 ext. 206
web: www.covaris.com

Agilent Technologies and Covaris Sign Co-Marketing Agreement Pairing Target Enrichment with DNA Shearing for Next-Gen Sequencing

SANTA CLARA, CA and WOBURN, MA—January 5, 2010—Agilent Technologies, Inc. (NYSE:A) and Covaris Inc. today announced a co-marketing agreement in which Covaris S2 DNA shearing technology will be marketed with the Agilent SureSelect Target Enrichment Systemto streamline next-generation sequencing experiments.

“Covaris provides an important sample preparation tool for shearing DNA evenly, and it has been adopted by next-generation sequencing thought leaders around the world,” said Fred Ernani, Ph.D., Agilent senior product manager for Emerging Genomic Applications. “As increasing numbers of investigators recognize the value of the SureSelect Target Enrichment System, they see even more value in combining it with Covaris’ DNA shearing technology.”

“Covaris is pleased to enter into this co-marketing arrangement with Agilent Technologies, a life sciences industry leader that recognizes the importance of controlling sample preparation to ensure quality results in sophisticated target selection applications,” said Jim Laugharn, Covaris president and CEO. “Advanced biological applications are currently experiencing exponential growth in data set output. Given this high level of production, it is even more critical to provide an engineered sample preparation process to control the quality of the starting material. We look forward to working with Agilent to bring high-quality sample preparation to SureSelect customers on a global basis.”

The Agilent SureSelect Target Enrichment System, introduced in February 2009, has been shown to greatly increase the speed and cost-efficiency of next-generation sequencing workflows used in life science research by enabling researchers to focus on genomic regions of interest rather than sequencing the entire genome. The Agilent system is based on an in-solution design, making it automation-friendly and easily scalable from 10 reactions through thousands, unlike other commercially available products for this application.

Agilent’s target-enrichment product line offers customer-specified mixtures of up to 55,000 biotinylated RNA probes, delivered in single tubes. The capture probes are 120 base pairs long, the longest currently on the market for this application. This makes the probes very effective at capturing DNA-containing unknown mutations, such as single nucleotide polymorphisms, insertions or deletions.

Users can design their own custom SureSelect mixtures using the Agilent eArray online design tool, which contains many key genomes and also lets users upload their own sequences. This intuitive, Web-based design tool is the heart of Agilent’s custom genomics product manufacturing capability and has now been expanded to the newer SureSelect platforms. eArray allows researchers to easily design the tools they need without up-front design fees.

The Covaris sample preparation technology, which is based on its patented Adaptive Focused Acoustic (AFA) technology, brings speed and efficiency to biological and chemical sample preparation. The Covaris method accelerates next-generation DNA sequencing sample preparation by providing a highly predictable and reproducible DNA shearing methodology to the next-gen workflow while limiting the amount of sample DNA lost in the shearing process.

“Since next-generation sequencing workflows are complex and sample failure is costly, Agilent chose to develop its SureSelect protocols using best practice,” Ernani said. “Incorporating Covaris’ shearing into our protocols made the most sense. So far, SureSelect customers have found our protocols to be very easy to follow and extremely robust, so I believe we’ve made a good choice to recommend the use of the Covaris S2.”

As part of the co-marketing agreement, Covaris has developed a special SureSelect Accessory Kit to help customers integrate the technology into their workflows. This adds significant value for SureSelect customers who choose to buy Covaris S2 systems. Agilent will continue to work with Covaris to develop new SureSelect protocols and products, leveraging the benefits of both products to provide next-generation sequencing users with the most robust tools for targeted re-sequencing.

About Covaris, Inc.
Covaris, Inc. is a rapidly growing life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid. Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, compound dissolution, drug metabolism tissue extraction, and much more. Covaris has sold more than 1,000 instruments in more than 25 countries around the world. Information about Covaris is available at www.covaris.com.

About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 17,000 employees serve customers in more than 110 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available on the Web at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.

Contacts:
Agilent
Stuart Matlow
Tel: +1 408-553-7191
e-mail: stuart_matlow@agilent.com

Covaris
Brian Paras
Tel: +1 781-932-3959, ext. 206
e-mail: bparas@covaris.com

Covaris Introduces DNA Shearing Service

WOBURN, MA—April 2, 2009—Covaris Incorporated today announced the introduction of DNA shearing service using Covaris instruments and technology.

Over the past few years, Covaris instruments have become the gold standard for DNA shearing application, as a sample preparation step for next generation sequencing. The Covaris process is validated and compatible with all next-gen sequencing platforms.  This process is highly reproducible and gives narrow size distribution. The isothermal, non-contact processing, in closed vessels, results in high recovery and no cross contamination, which are critical for any sequencing applications downstream.

“With the launch of our DNA shearing service, researchers can immediately take advantage of our technology without having to purchase the instrument first,” said Jim Laugharn, President and CEO of Covaris, “the service is ideal for several groups of customers–those who only need to process small amount of samples periodically; those who are waiting for capital budget approval for instrument purchase, and those who just want to evaluate the technology without long-term commitment. For these investigators, the DNA shearing service is a cost-effective way to “test drive” the Covaris AFA technology.”

The Covaris technology foundation is its proprietary and patented AFA (Adaptive Focused Acoustics™) technology. The Covaris AFA technology enables numerous non-contact, isothermal processes to be developed, for use in a broad range of applications in Genomics, Proteomics and Drug Discovery research, which could not be obtained prior to the development of AFA technology.

The DNA shearing service is a nice alternative sample prep tool for next-gen sequencing customers.  In addition, Covaris is introducing eCommerce capability on Covaris website.  This will enable customers to order commonly used consumables directly online.

About Covaris, Inc.
Covaris, Inc. is a rapidly growing life science instrument company.  Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid.  Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, Compound Dissolution, Drug Metabolism tissue extraction, and much more.

Information about Covaris is available at https://www.covaris.com.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
web: www.covaris.com